FDA Approves Arcutis’ Zoryve (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
RegulatoryapprovedZoryvePositive
AI Analysis
Summary
The FDA approved Arcutis' Zoryve (roflumilast) cream 0.3% for treating plaque psoriasis in children as young as age 2, expanding the drug's approved patient population.
Outcome Details
FDA approval for Zoryve (roflumilast) cream 0.3% for treatment of plaque psoriasis in children as young as age 2
Importance:8/10
Sentiment:
0.90
FDA approvalpediatric indicationdermatologyroflumilastplaque psoriasis
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on June 29, 2026 5:06 AM